Clinical trial
The Effect of Prolonged Multimodal Analgesia Strategy on Postoperative Pain in Patients Undergoing Spine Surgery
NCT07935252 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started November 2026. Interventional study, 132 participants (estimated). Lead sponsor Beijing Tiantan Hospital. Primary measure: Incidence of moderate-to-severe chronic pain at 3 months postoperatively.
How it compares
2,875 similar trials: same condition (Postoperative Pain) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effect of Prolonged Multimodal Analgesia Strategy on Postoperative Pain in Patients Undergoing Spine Surgery
- Lead sponsor
- Beijing Tiantan Hospital
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 10, 2026
- Completion date
- April 1, 2028
- Enrollment
- 132 (estimated)
- Sites
- Not reported
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: acute and chronic postsurgical pain
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Lead sponsor
- Beijing Tiantan Hospital
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| Prolonged Multimodal Analgesia Group | Experimental | Esketamine, dexmedetomidine, pregabalin |
Show registry wordingPre-operative (1 hour): pregabalin 150mg; Intraoperative: Esketamine 0.09 mg/kg/h pumping; Post-operative: Esketamine combined with dexmedetomidine PCA: the esketamine dosage is 0.06 mg/kg/h, dexmedetomidine dosage is 1.5 μg/kg, and the PCA pump is used for 48 hours; Pregabalin 75 mg bid in 1-7 days and Pregabalin 75 mg qd in 8-21days. The anesthesiologist may adjust the drug dosage as appropriate based on the patient's condition, and all medications administered must be documented in detail. drugs:Esketamine, dexmedetomidine, pregabalin device:Patient Controlled Analgesia(PCA) | ||
| Conventional Analgesia Group | Active comparator | Sufentanil |
Show registry wordingThe participant will be administrated by Sulfentanil PCA (1.5μg/kg) in postoperative 48h. The anesthesiologist may adjust the drug dosage as appropriate based on the patient's condition, and all medications administered must be documented in detail. | ||
Primary endpoints
Registered primary outcome measures; 1 primary.
| Measure | Time frame |
|---|---|
| Incidence of moderate-to-severe chronic pain at 3 months postoperatively | postoperative 3 months |
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Sufentanil
- US 11672738; expires February 2, 2038; assignee Vertical
- US 8945592; expires July 29, 2031; assignee Talphera, Inc.
- US 8202535; expires October 22, 2030; assignee Talphera, Inc.
- US 8865743; expires October 22, 2030; assignee Talphera, Inc.
- US 10896751; expires March 16, 2030; assignee Talphera, Inc.
- +16 more patents
Lead sponsor's other trials
Beijing Tiantan Hospital, most recent start first.
+485 more trials
Similar trials
Same condition (Postoperative Pain) and phase, most recent start first.
+2,870 more trials See the condition page